432 related articles for article (PubMed ID: 22836783)
1. Incidence of atypical nontraumatic diaphyseal fractures of the femur.
Dell RM; Adams AL; Greene DF; Funahashi TT; Silverman SL; Eisemon EO; Zhou H; Burchette RJ; Ott SM
J Bone Miner Res; 2012 Dec; 27(12):2544-50. PubMed ID: 22836783
[TBL] [Abstract][Full Text] [Related]
2. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
3. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
5. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
[TBL] [Abstract][Full Text] [Related]
7. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.
Meier RP; Perneger TV; Stern R; Rizzoli R; Peter RE
Arch Intern Med; 2012 Jun; 172(12):930-6. PubMed ID: 22732749
[TBL] [Abstract][Full Text] [Related]
8. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.
Napoli N; Jin J; Peters K; Wustrack R; Burch S; Chau A; Cauley J; Ensrud K; Kelly M; Black DM
J Clin Endocrinol Metab; 2012 Jul; 97(7):2414-22. PubMed ID: 22547423
[TBL] [Abstract][Full Text] [Related]
9. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry.
Lee YK; Byun DW; Jung SM; Kwon HY; Kim HY; Kim SH; Kim TY; Jang S; Ha YC
Calcif Tissue Int; 2019 Mar; 104(3):313-319. PubMed ID: 30446771
[TBL] [Abstract][Full Text] [Related]
11. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
[TBL] [Abstract][Full Text] [Related]
12. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
13. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.
Shane E; Burr D; Ebeling PR; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster D; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Koval K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Sen HT; van der Meulen MC; Weinstein RS; Whyte M;
J Bone Miner Res; 2010 Nov; 25(11):2267-94. PubMed ID: 20842676
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate use and atypical fractures of the femoral shaft.
Schilcher J; Michaëlsson K; Aspenberg P
N Engl J Med; 2011 May; 364(18):1728-37. PubMed ID: 21542743
[TBL] [Abstract][Full Text] [Related]
16. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
17. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-associated atypical subtrochanteric femur fracture.
Wolin EA; Banks KP; Vroman PJ
J Nucl Med Technol; 2015 Mar; 43(1):72-3. PubMed ID: 25125450
[TBL] [Abstract][Full Text] [Related]
19. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.
Lo JC; Grimsrud CD; Ott SM; Chandra M; Hui RL; Ettinger B
Osteoporos Int; 2019 Dec; 30(12):2515-2520. PubMed ID: 31555883
[TBL] [Abstract][Full Text] [Related]
20. Risk of atypical femoral fracture during and after bisphosphonate use.
Schilcher J; Koeppen V; Aspenberg P; Michaëlsson K
Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
